ethyl 9-phenylpropyl-β-carboline-3-carboxylate | 752212-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 9-phenylpropyl-β-carboline-3-carboxylate
• 英文别名: Ethyl 9-phenylpropyl-beta-carboline-3-carboxylate；ethyl 9-(3-phenylpropyl)pyrido[3,4-b]indole-3-carboxylate
• CAS: 752212-92-3
• 化学式: C₂₃H₂₂N₂O₂
• 分子量: 358.44
• InChiKey: HYSQOUBTTBCQJO-UHFFFAOYSA-N

物化性质

• 熔点：
  140-142 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  513.1±50.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 9-phenylpropyl-β-carboline-3-carboxylate 在 hydrazine hydrate 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 N'-((9H-pyrido[3,4-b]indol-3-yl)methylene)-9-(3-phenylpropyl)-9H-pyrido[3,4-b]indole-3-carbohydrazide
  参考文献：
  名称：

  新型 N-酰基腙键连接的杂二价 β-咔啉作为潜在抗癌剂的设计、合成和生物学评价

  摘要：

  利用药效团杂交方法，我们设计并合成了一系列新的 28 种新型异二价 β-咔啉。评估了每种化合物对不同来源（鼠类和人）的五种癌细胞系（LLC、BGC-823、CT-26、Bel-7402 和 MCF-7）的体外细胞毒性潜力，目的是确定化合物的效力和选择性。化合物 8z 显示出抗肿瘤活性，半数最大抑制浓度 (IC50) 值为 9.9 ± 0.9、8.6 ± 1.4、6.2 ± 2.5、9.9 ± 0.5 和 5.7 ± 1.2 µM，对测试的五种癌细胞系。此外，使用鸡绒毛尿囊膜 (CAM) 体内模型研究了化合物 8z 对血管生成过程的影响。在 5 μM 的浓度下，化合物 8z 显示出对血管生成的积极影响。

  DOI：

  10.3390/molecules24162950
• 作为产物：
  描述：

  2,3,4,9-四氢-1H-beta-咔啉-3-甲酸 在 氯化亚砜 、 sodium hydride 、 sulfur 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 ethyl 9-phenylpropyl-β-carboline-3-carboxylate
  参考文献：
  名称：

  Synthesis and biological evaluation of piperazine group-linked bivalent β-carbolines as potential antitumor agents

  摘要：

  一系列具有3-亚甲基单元之间的哌嗪基间隔的二价β-咔啉类化合物被合成，并评估了它们的体外细胞毒活性。化合物7e和7g表现出强大的细胞毒活性。

  DOI：

  10.1039/c5md00312a

文献信息

• Synthesis, acute toxicities, and antitumor effects of novel 9-substituted β-carboline derivatives
  作者：Rihui Cao、Qi Chen、Xuerui Hou、Hongsheng Chen、Huaji Guan、Yan Ma、Wenlie Peng、Anlong Xu

  DOI：10.1016/j.bmc.2004.06.038

  日期：2004.9

  A series of novel 9-substituted beta-carboline derivatives was synthesized from harmine and l-tryptophan, respectively. Cytotoxic activities of these compounds in vitro were investigated. The results showed that most compounds of 9-substituted beta-carboline derivatives had more remarkable cytotoxic activities in vitro than their corresponding parent compounds. Acute toxicities and antitumor effects

  分别从甜蜜素和色氨酸合成了一系列新颖的9-取代的β-咔啉衍生物。研究了这些化合物在体外的细胞毒活性。结果表明，大多数9-取代的β-咔啉衍生物的化合物在体外具有比其相应母体化合物更显着的细胞毒活性。还检查了选定的β-咔啉衍生物在小鼠中的急性毒性和抗肿瘤作用。结果表明，位置9处的短烷基或苄基取代基显着提高了抗肿瘤活性，位置3处的乙氧羰基或羧基取代基显着降低了这些β-咔啉衍生物的急性毒性和神经毒性。而且，与其他化合物相比，在第3位具有烷氧基羰基或羧基取代基且在第9位具有短烷基或苄基取代基的化合物均表现出更显着的抗肿瘤活性以及较低的急性毒性和神经毒性。发现分别在第9位和第3位具有正丁基和羧基取代基的化合物8c具有最高的抗肿瘤作用和最低的急性毒性和神经毒性。这些数据表明：（1）β-咔啉衍生物第9位和第3位的适当取代基可能在确定其增强的抗肿瘤活性以及降低的急性毒性和神经毒性作用方面起着至关重要的作用；
• Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo
  申请人：Wu Jialin

  公开号：US20090227619A1

  公开（公告）日：2009-09-10

  This invention relates to compounds of general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumour activity and lower nervous system toxicity by structurally modification of the parent structure of β-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumour medicines and medicines used in treatment of tumour diseases in combination of light or radiation therapy.

  本发明涉及一般式（I）的化合物，其中R1、R2、R3、R4和R5如规范中所定义；用于它们的制备的中间体，制备方法和使用。本发明通过在β-噻吩类似物的母体结构的1、2、3、7和9位进行结构修饰，产生具有增强抗肿瘤活性和较低神经系统毒性的新的harmine衍生物。本发明的化合物可以轻松高产制备。它们可以用于制造各种抗肿瘤药物和用于结合光或放射治疗治疗肿瘤疾病的药物。
• Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof
  申请人：Wu Jialin

  公开号：US08772311B2

  公开（公告）日：2014-07-08

  This invention relates to compounds of general formula (I), wherein R1, R2, R3, R4 and R5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumor activity and lower nervous system toxicity by structurally modification of the parent structure of β-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumor medicines and medicines used in treatment of tumor diseases in combination of light or radiation therapy.

  本发明涉及通式（I）的化合物，其中R1，R2，R3，R4和R5如规范中所定义；用于其制备的中间体，制备过程以及其用途。本发明通过在β-咔啉毒素的母体结构的1、2、3、7和9位进行结构修饰，产生具有增强的抗肿瘤活性和较低的神经系统毒性的新的哈曼衍生物。本发明的化合物可以轻松地高产制备。它们可以用于制造各种抗肿瘤药物和联合光或放射治疗用于治疗肿瘤疾病的药物。
• HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF
  申请人：Xinjiang Huashidan Pharmaceutical Research Co., Ltd.

  公开号：EP1634881B1

  公开（公告）日：2011-07-27
• Design, synthesis and 3D-QSAR of β-carboline derivatives as potent antitumor agents
  作者：Rihui Cao、Xiangdong Guan、Buxi Shi、Zhiyong Chen、Zhenhua Ren、Wenlie Peng、Huacan Song

  DOI：10.1016/j.ejmech.2010.02.036

  日期：2010.6

  In a continuing effort to develop novel beta-carbolines endowed with better pharmacological profiles, a series of beta-carboline derivatives were designed and synthesized based on the previously developed SARs. Cytotoxicities in vitro of these compounds against a panel of human tumor cell lines were also investigated. The results demonstrated that the N(2)-benzylated beta-carbolinium bromides 56-60 represented the most potent compounds with IC(50) values lower than 10 mu M. The application of 3D-QSAR to these compounds explored the structural basis for their biological activities. CoMFA (q(2) = 0.513, r(2) = 0.862) and CoMSIA (q(2) = 0.503, r(2) = 0.831) models were developed for a set of 47 beta-carbolines. The results indicated that the antitumor pharmacophore of these molecules were marked at position-1, -2, -3, -7 and -9 of beta-carboline ring.